Remdesivir (RDV; GS-5734) for the Treatment of Selected Coronavirus (CoV) Infection, Single Patient Protocol


An experimental treatment called Remdesivir was provided on a compassionate-use basis to patients hospitalized with COVID-19, an illness caused by infection with SARS-CoV-2.

Study Type/Phase: Emergency Investigational New Drug
Enrollment Status: Not Recruiting

There is no approved therapy for COVID-19, and current management consists of supportive care, including oxygen support and treatment with antibiotics. In previous experiments, Remdesivir has shown activity against other similar types of viruses, including filoviruses (e.g., Ebola) and coronaviruses (e.g., SARS-CoV and MERS-CoV). Laboratory testing has also shown that Remdesivir has activity against SARS-CoV-2.

Patients were eligible to receive treatment if they had confirmed SARS-CoV-2 infection with an oxygen saturation of 94% or less while they were breathing ambient air or who were receiving oxygen support. Patients received Remdesivir for 10 days while admitted to the hospital.

Principal Investigator

Daniel Shin, MD


Gilead Sciences, Inc.


Kara Turner, Clinical Research Coordinator
Taft Center for Clinical Research


For more information about this clinical trial, including trial status, eligibility and full trial listing, visit